Tiger Brokers

  • Quotes
  • Products
    • Cash Boost Account
    • US Stocks
    • US Fractional Shares
    • HK Stocks
    • China A-shares
    • Options
    • Futures
    • US Treasury
    • Auto-invest
    • Fixed Coupon Notes
    • Tiger BOSS Debit Card
    • Fund Mall
    • Tiger Vault
    • Tiger Open Platform
    • Wealth
  • Pricing
    • Prime
      • Stocks & ETFs
      • Options, Warrants & CBBCs
      • Futures
      • Bonds
      • Fund Mall
    • Cash Boost
      • Stocks & ETFs
    • Financing Interest Rates
  • Promotions
  • Help
    • Account Operations
      • How to Open an Account?
      • Account Opening Documents
      • Account Types Available
    • Transfer & Pay
      • Account Funding
      • DDA Fast Deposit
      • Funds Withdrawal
      • Shares Transfer-in
      • Shares Transfer-out
      • Currency Conversion
    • Products & Trading
      • Products Available
      • Order Types
      • Trading Rules
      • Declaration
    • Margin Trading & Short Selling
      • Margin & Leverage
      • Risk Management
      • Short Selling Risk
    • Fund Mall
      • Open a fund account and transaction
    • Cash Boost Account
      • Cash Boost Account FAQ
      • How to Open Cash Boost Account
      • How to Contra Trade using Cash Boost Account
      • How to link your CDP Securities Account
    • Tiger Boss Debit Card
      • Frequently Asked Questions
      • Fees of the Debit card
      • How to Top-up
      • How to use my Debit card
    • Tiger Vault
      • Features of Tiger Vault
      • Transaction Fees
    • Statement
      • Statement
      • Dividends
  • Learn
  • TigerAI
  • Institution
    • Wealth and asset manager
    • Proprietary trading institutions
    • Introducing brokers
    • Third-party service provider
  • Careers
    • L.E.A.P Programme
    • Investment Representative
    • Careers Portal
  • LOGIN
  • SIGN UP
US StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZyVersa Therapeutics, Inc.

0.1846
-0.1267-40.70%
Volume:1.71M
Turnover:332.88K
Market Cap:899.64K
PE:-0.02
High:0.2520
Open:0.1546
Low:0.1546
Close:0.3113
Loading ...
OverviewCompanyNewsFilings

Zyversa Therapeutics: Initiating Small Phase 2a Proof-of-Concept Trial With Var 200 in First Half of 2025 in Patients With Dkd

THOMSON REUTERS
·
08 Apr

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)

GlobeNewswire
·
08 Apr

ZyVersa Therapeutics files to sell 4.21M shares of common stock for holders

TIPRANKS
·
05 Apr

ZyVersa Therapeutics FY24 EPS $(8.48) Up From $(1,089.70) YoY

Benzinga
·
27 Mar

Press Release: ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
27 Mar

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

GlobeNewswire
·
18 Mar

ZyVersa Therapeutics prices 2.1M shares at 95c in private placement

TIPRANKS
·
06 Mar

Zyversa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced at the Market

THOMSON REUTERS
·
06 Mar

ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition

TIPRANKS
·
05 Mar

Analyst Rate

 
 
 
 

Corporate Actions

Delist
Jul 17, 2025
Financial Report Announcement
May 12, 2025 Post Market
Financial Report Announcement
Mar 27, 2025 Pre-Market
Financial Report Announcement
Nov 14, 2024 Pre-Market
Financial Report Announcement
Aug 09, 2024 Post Market

Dividend History

no data

No relevant data is available

Valuation Analysis

-0.30
Current
-2.55
Sector Average
48.13%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
-0.30
Maximum
-0.01
+1 STD
1.28
Minimum
-10.65
-1 STD
-6.38
Average
-2.55

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Fintech (Singapore) Pte. Ltd.
Email Address:
uservice@ttm.financial
User Agreement|Privacy Policy

Copyright © Tiger Fintech (Singapore) Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.